concept

NEUROPROTECTION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NEUROPROTECTION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

328Connections

13Hypotheses

16Analyses

31Outgoing

50Incoming

3Experiments

20Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	NEUROPROTECTION
Key Genes/Proteins	Aucubin
Related Diseases	NEURODEGENERATION

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Sulforaphane and Nrf2 Activation for Neuroprotection

therapeutic · 4477 words

→

Pathway Diagram

graph TD
    NEUROPROTECTION["NEUROPROTECTION"]
    style NEUROPROTECTION fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    NEUROPROTECTION -.->|"protects against"| Glaucoma["Glaucoma"]
    NEUROPROTECTION -.->|"protects against"| Neurodegeneration["Neurodegeneration"]
    NEUROPROTECTION -.->|"protects against"| Axonal_Damage(Axonal Damage)
    NEUROPROTECTION -.->|"protects against"| major_depressive_disorder["major depressive disorder"]
    NEUROPROTECTION -.->|"inhibits"| NEURODEGENERATION(NEURODEGENERATION)
    NEUROPROTECTION -.->|"protects against"| PPAR["PPAR"]
    NEUROPROTECTION -.->|"protects against"| VDR["VDR"]
    NEUROPROTECTION -.->|"protects against"| PARKIN["PARKIN"]
    NEUROPROTECTION -->|"activates"| NRF2["NRF2"]
    Connexin43_Hemichannel_Blockad["Connexin43 Hemichannel Blockade"] -->|"mediates"| NEUROPROTECTION
    MT1([MT1]) -->|"involved_in"| NEUROPROTECTION
    MT2([MT2]) -->|"involved_in"| NEUROPROTECTION
    Tudca["Tudca"] -->|"mediates"| NEUROPROTECTION
    AKT([AKT]) -->|"involved_in"| NEUROPROTECTION
    METALLOTHIONEIN([METALLOTHIONEIN]) -->|"mediates"| NEUROPROTECTION
    METALLOTHIONEIN_I_II([METALLOTHIONEIN-I+II]) -->|"involved_in"| NEUROPROTECTION
    PPARG["PPARG"] -->|"mediates"| NEUROPROTECTION
    BDNF_TrkB_signaling["BDNF/TrkB signaling"] -->|"promotes"| NEUROPROTECTION
    microglial_APOE4_deletion["microglial APOE4 deletion"] -->|"promotes"| NEUROPROTECTION

Outgoing (31)

Target	Relation	Type	Str
Neurodegeneration	protects_against	process	0.85
Axonal Damage	protects_against	phenotype	0.85
Glaucoma	protects_against	disease	0.85
major depressive disorder	protects_against	disease	0.80
Alzheimer's Disease	protects_against	disease	0.75
NEURODEGENERATION	inhibits	phenotype	0.64
PPAR	protects_against	entity	0.60
PPAR	activates	entity	0.60
VDR	protects_against	entity	0.60
PARKIN	protects_against	entity	0.60
NRF2	activates	entity	0.60
PI3K	activates	entity	0.60
SLC7A11	activates	entity	0.60
STROKE	protects_against	entity	0.60
NLGN3	activates	entity	0.60
STROKE	biomarker_for	entity	0.60
NRF2	inhibits	entity	0.60
SLC7A11	inhibits	entity	0.60
STROKE	inhibits	entity	0.60
REMYELINATION	inhibits	concept	0.50
MICROGLIAL ACTIVATION	activates	concept	0.50
PI3K/AKT SIGNALING	activates	concept	0.50
CENTRAL NERVOUS SYSTEM	decreases_risk	concept	0.50
ISCHEMIC STROKE	inhibits	concept	0.50
MAPK SIGNALING	activates	concept	0.50
IGF-1	activates	concept	0.50
QUERCETIN	interacts_with	concept	0.50
GLIOSIS	activates	concept	0.50
CENTRAL NERVOUS SYSTEM	activates	concept	0.50
ISCHEMIC STROKE	protects_against	concept	0.50
ISCHEMIC STROKE	activates	concept	0.50

Incoming (297)

Source	Relation	Type	Str
Tudca	mediates	compound	0.95
AKT	involved_in	protein	0.95
Connexin43 Hemichannel Blockade	mediates	mechanism	0.95
mitochondrial_transfer	mediates	mechanism	0.95
MT2	involved_in	protein	0.95
METALLOTHIONEIN	mediates	protein	0.95
MT1	involved_in	protein	0.95
METALLOTHIONEIN-I+II	involved_in	protein	0.95
BDNF/TrkB signaling	promotes	pathway	0.92
microglial APOE4 deletion	promotes	process	0.91
Lactate	protective_against	metabolite	0.90
mitochondrial_transfer	contributes_to	mechanism	0.90
NO	mediates	compound	0.90
TGR5	mediates	receptor	0.90
Methylene Blue	promotes	drug	0.90
INTESTINAL NHR-86	mediates	protein	0.90
Gd3 Synthase	mediates	enzyme	0.90
Microglia	mediates	cell_type	0.90
Cerebral Insulin Signaling	mediates	pathway	0.90
GJA1	modulates	protein	0.90
Berberine-Inspired Ionizable Lipid	promotes	compound	0.90
Connexin43 Hemichannel Blockade	activates	mechanism	0.90
Astrocytes	mediates	cell_type	0.90
Atremorine	mediates	compound	0.88
mitophagy	promotes	process	0.88
APOE4	inhibits	gene	0.88
BDNF	mediates	gene	0.88
Hk2-Pink1 Pathway	mediates	pathway	0.88
mitophagy enhancement	promotes	process	0.87
AMPK	mediates	protein	0.85
PRKN	mediates	protein	0.85
Mitochondrial Homeostasis	involved_in	process	0.85
MicroRNAs	mediates	biomarker	0.85
Long Non-Coding RNAs	mediates	biomarker	0.85
BDNF	promotes	gene	0.85
Astrocytes	involved_in	cell_type	0.85
STING Inhibition	protects_against	mechanism	0.85
BDNF	mediates	gene	0.85
Macrophage/Microglia Autophagy	protects_against	process	0.85
PPARGC1A	mediates	gene	0.85
A2 Astrocytes	mediates	cell_type	0.85
HDAC3 Inhibition	mediates	mechanism	0.85
Parkin Phosphorylation	mediates	mechanism	0.85
MAPK Signaling Pathway	mediates	pathway	0.85
Pi3K/Akt Pathway	mediates	pathway	0.85
SHH signaling pathway	mediates	pathway	0.85
PKC/ERK	promotes	pathway	0.85
Antioxidant Enzymatic Systems	involved_in	pathway	0.85
PRKN	protects_against	protein	0.85
Exosome-Based Treatments	promotes	drug	0.85

Targeting Hypotheses (13)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neurop	0.844	neurodegeneration	Gene Co-expression Network Analysis of A
NRF2 Activation Provides Neuroprotection Across ALS, AD, and	0.710	neurodegeneration	Test Preregistration Analysis
Ferroptosis Inhibition for α-Synuclein Neuroprotection	0.705	neurodegeneration	Gene expression changes in aging mouse b
GLUT1-Mediated Glucose Flux Coefficient as Neuroprotection I	0.685	translational neuroscience	Which metabolic biomarkers can distingui
CX3CL1-CX3CR1 Mimetic Therapy for Neuroprotection	0.635	neurodegeneration	Microglial subtypes in neurodegeneration

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against T	0.604	neurodegeneration	Should microtubule-stabilizing drugs be
Female Microglia Exhibit Reduced P2Y12 Expression Conferring	0.580	neuroinflammation	How do regional, age, and sex-dependent
Purine Salvage Pathway Flux as Neuroprotection Efficacy Mark	0.565	translational neuroscience	Which metabolic biomarkers can distingui
CSF1R Partial Agonism Combined with TREM2 Activation for ALS	0.535	neurodegeneration	Microglial subtypes in neurodegeneration
Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neur	0.503	translational neuroscience	Which metabolic biomarkers can distingui
Mitochondrial-Targeted PINK1/Parkin Pathway Activation for N	0.500	neurodegeneration	Test Hypothesis Fixtures
Time-Restricted High-Dose Melatonin for Acute Neuroprotectio	0.445	-	What is the optimal dosage and timing of
Microbiome-Derived Tryptophan Metabolite Neuroprotection	0.427	neurodegeneration	What are the mechanisms by which gut mic

Mentioning Analyses (16)

Scientific analyses that reference this entity

What is the minimum effective dose of trazodone required for disease-modifying e

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.605

Gene Regulatory Network Inference in Alzheimer's Disease

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.661

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh

neurodegeneration | 2026-04-11 | 0 hypotheses

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

neurodegeneration | 2026-04-10 | 0 hypotheses

Experiments (3)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
S-equol-induced ferroptosis mechanism in TNBC cells	exploratory	Triple negative breast cancer	0.900	0.00	TNBC cell lines	proposed	N/A
Gandouling protection against brain injury in Wilson's disease via SIR	validation	Hepatolenticular degeneration	0.900	0.00	TX mice (Wilson's disease mode	proposed	N/A
Conditional TYROBP Knockdown in Early-Stage 5xFAD Mice Using CRISPRi-A	in_vivo	Alzheimer's disease	0.746	0.55	5xFAD x Cx3cr1-Cre mice inject	abandoned	$95,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Genome-wide consensus transcriptional signatures identify synaptic pruning linki [PMID:41139712]	Li H, Xie Z, Tian Y, Zhou R, Yang Y et a	Mol Psychiatry	2026
The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively reg [PMID:41435829]	Rosner D, Sun J, Cacace R, Yee A, Wagh C	Neuron	2026
GPX4 promotes optic nerve regeneration and retinal ganglion cell neuroprotection [PMID:41485051]	Yang M, Bian F, Feng X, Li L, Huang H et	Mol Ther	2026
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors. [PMID:41494530]	Liu J, Cai X, Lin J, Zhang Z, Zhou Q et	Cell	2026
Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways [PMID:41516398]	Gromadzka G, Tarnacka B, Cieślik M	Int J Mol Sci	2026
Integrative Transcriptomic and Bioinformatics Approaches Combined With Transform [PMID:41524613]	Yan D, Li W, Xing E, Wang P, Zhang Z	FASEB J	2026
Ferroptosis in neurological diseases: moving towards therapeutic intervention. [PMID:41554903]	Tuo QZ, Bush AI, Lei P	Mol Psychiatry	2026
Fin(e)-tuning ferroptosis. [PMID:41576911]	Szylo KJ, Dixon SJ	Mol Cell	2026
GPX4-dependent ferroptosis governs ILC2 homeostasis and colitis progression. [PMID:41663525]	Liu G, Wang Y, Huang H, Wang J, Yang J e	Cell Mol Immunol	2026
A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth s [PMID:41720096]	Xia Z, Yang X, Samovich SN, Tyurina YY,	Cell	2026
The crossroads of inflammation and oxidative stress: A review of the interplay b [PMID:41722697]	Park WH	Pharmacol Res	2026
Ferroptosis in Cerebral Ischemia/Reperfusion Injury: Mechanistic Drivers and The [PMID:41738060]	Song C, Liu Z, Tang J, Huang Y	Neuropsychiatr Dis Treat	2026
Decoding GPX4 regulation in ferroptosis: mechanisms and therapeutic implications [PMID:41826143]	Chen X	Trends Mol Med	2026
Integrative bioinformatics and machine learning identify shared molecular mechan [PMID:41961800]	Deng A, Wang W	PLoS One	2026
Montelukast Modulates MPTP-induced Ferroptosis and Neuroinflammation Linked To t [PMID:41712018]	["Jung Yu Jin", "Choi Hyunsu", "Lee Seon	Neuromolecular medicine	2026
A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis. [PMID:41349546]	Lorenz SM, Wahida A, Bostock MJ, Seibt T	Cell	2026
Genome-wide consensus transcriptional signatures identify synaptic pruning linki [PMID:41139712]	Li H, Xie Z, Tian Y, Zhou R, Yang Y, Lin	Molecular psychiatry	2026
The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively reg [PMID:41435829]	Rosner D, Sun J, Cacace R, Yee A, Wagh C	Neuron	2026
Hypoxia-inducible factor-1 as targets for neuroprotection : from ferroptosis to [PMID:39466326]	["Changyong Wang", "Shanyu Lv", "Hongyan	Neurological sciences : offici	2025
Gentiopicroside Attenuated Dopaminergic Neurodegeneration via Inhibiting Neuroin [PMID:40256942]	Unknown	Basic & clinical pharmacol	2025

Debates (20)

Multi-agent debates referencing this entity

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Microbial Inflammasome Priming Prevention

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

What is the minimum effective dose of trazodone required for disease-modifying e

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

What are effective therapeutic strategies for targeting APOE4 in Alzheimer's dis

closed · Rounds: 4 · Score: 0.82 · 2026-04-22

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

closed · Rounds: 0 · Score: 0.66 · 2026-04-21

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

closed · Rounds: 0 · Score: 0.64 · 2026-04-21

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

Related Research

Hypotheses and analyses mentioning NEUROPROTECTION in their description or question text

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili

Score: 0.604 · neurodegeneration · 2026-04-15

## Mechanistic Overview DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization starts fr

Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Thr

Score: 0.580 · neuroinflammation · 2026-04-22

## Mechanistic Overview Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Through Attenuated

Purine Salvage Pathway Flux as Neuroprotection Efficacy Marker

Score: 0.565 · translational neuroscience · 2026-04-16

## Mechanistic Overview Purine Salvage Pathway Flux as Neuroprotection Efficacy Marker starts from the claim that modula

CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection

Score: 0.535 · neurodegeneration · 2026-04-25

Premature investment. The Expert identifies that no validated partial CSF1R agonist exists—creating partial agonism for

Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neuroprotection

Score: 0.503 · translational neuroscience · 2026-04-12

## Mechanistic Overview Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neuroprotection starts from the claim th

Mitochondrial-Targeted PINK1/Parkin Pathway Activation for Neuroprotection

Score: 0.500 · neurodegeneration · 2026-04-26

PINK1 loss-of-function prevents Parkin recruitment to damaged mitochondria, blocking mitophagy. Urolithin A is proposed

Time-Restricted High-Dose Melatonin for Acute Neuroprotection

Score: 0.445 · unknown disease · 2026-04-26

Nightly 10mg melatonin dosing attenuates Aβ42-induced neurotoxicity through MT1-mediated suppression of PERK/CHOP apopto

Microbiome-Derived Tryptophan Metabolite Neuroprotection

Score: 0.427 · neurodegeneration · 2026-04-02

Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which

NEUROPROTECTION

Understanding Entity Pages

Wiki Pages (1)

Sulforaphane and Nrf2 Activation for Neuroprotection

Pathway Diagram

Outgoing (31)

Incoming (297)

Targeting Hypotheses (13)

Mentioning Analyses (16)

What is the minimum effective dose of trazodone required for disease-modifying e

Gene Regulatory Network Inference in Alzheimer's Disease

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

Neuroinflammation and microglial priming in early Alzheimer's Disease

Which metabolic biomarkers can distinguish therapeutic response from disease pro

How do astrocyte-neuron metabolic interactions change during disease progression

What determines the optimal timing and dosing of ketogenic interventions for neu

APOE4 targeting in neurodegeneration

Astrocyte Reactivity Subtypes in Neurodegeneration

Lipid raft composition changes in synaptic neurodegeneration

APOE4 structural biology and therapeutic targeting strategies

Neuroinflammation resolution mechanisms and pro-resolving mediators

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (3)

Related Papers (20)

Debates (20)

Extended debate: CYP46A1 Overexpression Gene Therapy

Hypothesis debate: Membrane Cholesterol Gradient Modulators

Hypothesis debate: Microbial Inflammasome Priming Prevention

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

What is the minimum effective dose of trazodone required for disease-modifying e

What are effective therapeutic strategies for targeting APOE4 in Alzheimer's dis

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

Mechanistic validation of SEA-AD differential expression hypotheses: Complement

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

Related Research

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili

Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Thr

Purine Salvage Pathway Flux as Neuroprotection Efficacy Marker

CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection

Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neuroprotection

Mitochondrial-Targeted PINK1/Parkin Pathway Activation for Neuroprotection

Time-Restricted High-Dose Melatonin for Acute Neuroprotection

Microbiome-Derived Tryptophan Metabolite Neuroprotection